The current Ebolavirus (EBOV) outbreak in West Africa remains uncontrolled, partially because there are still no approved vaccines or therapeutics to prevent or treat these infections. In the decade prior to 2014, many EBOV vaccines candidates had been identified though none had progressed to registration for clinical use in humans. This latest and largest EBOV outbeak has renewed the urgency for an effective and safe vaccine strategy to combat further epidemics. Several EBOV vaccine candidates have now advanced to human clinical trials. These vaccines are based on their ability to elicit immune responses against EBOV glycoproteins (GPs; the major viral immunogens): DNA-based vaccines; replication-incompetent chimpanzee recombinant adenoviruses (rAds); and live-attenuated recombinant vesicular stomatitis viruses (rVSVs). This presentation will review the current status and future of EBOV vaccines.